Digest Réseau Comment ça marche
Réseau
/
Sociétés
Bo
Non vérifié

Boehringer Ingelheim Limited

Ce que nous écrivons

Annonces ÉconomiquesIndustrie pharmaceutiqueManagement/Organisation d'EntrepriseMédecine Santé Bien-êtrePublicité/Marketing/Médias/Communication

49 communiqués de presse

Voir tous les communiqués de presse
07/06/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
12/05/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
29/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim and Eko Health Inc. launch new AI-based solution that detects heart murmurs in dogs
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
27/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
20/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
15/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
13/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
09/04/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
09/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
24/03/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0